Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice? – PubMed
Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice?
Related Articles
Medical Board of California
The Medical Board of California licenses and disciplines doctors, handles complaints against physicians and offers public-record information.
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
Germline mutations in DNA repair genes are prevalent in myeloma patients and correlate with duration of response to a frontline genotoxic therapy.
The Heterogeneous Syndrome of Noninfectious Causes of Persistent Fever in Neutropenic Patients With Hematologic Malignancy: Another Opportunity for Stewardship?
Abstract. Although occult fungal, viral, and multidrug-resistant bacterial infections can cause persistent fever in neutropenic patients with hematologic c
After Being Evacuated amid L.A. Fires, Doctor’s Family Follows Him to Hospital to Help Cancer Patients: ‘We’re Not Going to Leave You’
Dr. Ravi Salgia is an oncologist at City of Hope cancer center. When he and his wife and adult daughter were evacuated from their Pasadena…
Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment | COR2ED
PDAC is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens
Are some cases of Alzheimer’s disease caused by infection? – Harvard Health
Some scientists believe that microbes might play a part in Alzheimer’s disease development. There are several theories about how and why this occurs. Microbes that…
The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma
Antibody-drug conjugates (ADCs) are a rapidly evolving class of anti-cancer drugs with a significant impact on management of hematological malignancies including diffuse large B-cell lymphoma…
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added to Pd for the treatment…
Opinion | What Botox Teaches Us About Serendipity in Clinical Encounters
Don’t forget the power of a strong doctor-patient relationship
Why are kids sick all the time? Experts weigh in
Canada Healthwatch | The most important health news, in one place. 🍁
